JP2020176145A
|
|
Combination treatment for hematological cancers
|
WO2020112854A1
|
|
Methods of treating myelodysplastic syndrome
|
AU2019315406A1
|
|
Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor
|
CA3069010A1
|
|
Methods of treating myelodysplastic syndrome
|
TW201706284A
|
|
Methods of polynucleotide preparation using multivalent cation salt compositions
|
CA2925500A1
|
|
Phosphorodiamidate backbone linkage for oligonucleotides
|
JOP20200257A1
|
|
Oligonucleotide Compositions and Methods of Making the Same
|
US2015344963A1
|
|
Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
|
BR112015012507A2
|
|
in vitro method of selecting an individual diagnosed or suspected of having cancer and using a telomerase inhibitor
|
US2015342982A1
|
|
Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
|
CN111617252A
|
|
Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative tumors
|
CA2887702A1
|
|
C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
|
US2014163090A1
|
|
Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
|
US2014121261A1
|
|
C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
|
US2014155465A1
|
|
Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
|
CA2857490A1
|
|
Guanine analogs as telomerase substrates and telomere length affectors
|
CA2829804A1
|
|
Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells
|
AU2012236880A1
|
|
Telomere length measurement in formalin-fixed, paraffin embedded (FFPE) samples by quantitative PCR
|
WO2011106671A1
|
|
Assay for telomerase activity
|
WO2010151782A1
|
|
Differentiated pluripotent stem cell progeny depleted of extraneous phenotypes
|